Magnesium Taurate for Health & Longevity

Evidence Review created on 08/23/2026 using AI4L / Grok 4

Also known as: Magnesium Ditaurate, Magnesium Taurinate, Magnesium Bis(2-aminoethanesulfonate), Mg Taurate

Motivation

Magnesium taurate is a dietary supplement in which the essential mineral magnesium is bound to taurine, a sulfur-containing amino acid concentrated in heart, muscle, and brain. Interest in this pairing comes from the idea that both nutrients tend to lower free calcium inside cells, a shared action that could support blood pressure more efficiently than either nutrient alone.

The compound was proposed in the mid-1990s as an oral magnesium source that would also deliver taurine, and it remains a specialty salt rather than the magnesium form most people are offered first. Most of what is known about blood pressure, sleep, and metabolic effects still comes from magnesium or taurine studied separately. Direct human trials of magnesium taurate itself are scarce. A chemically related product, magnesium acetyl taurate, is often mixed up with it but is not the same salt.

This review examines the evidence that magnesium taurate, as a specific oral magnesium source, can support health and longevity aims—chiefly blood pressure, metabolic markers, and sleep—alongside its risks, interactions, and practical use.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Magnesium taurate

Dedicated Grokipedia article covering chemistry, synthesis, proposed cardiovascular uses, and the preclinical (mostly animal) evidence base for this salt.

Examine

No dedicated Examine.com article for magnesium taurate was found as of 23 August 2026.

ConsumerLab

No dedicated ConsumerLab article for magnesium taurate was found as of 23 August 2026.

Systematic Reviews

No systematic reviews or meta-analyses for Magnesium Taurate were found on PubMed as of 23 August 2026. Neither the claimed cardiovascular effect nor the principal gastrointestinal risk is represented by a systematic review of this salt.

Mechanism of Action

Magnesium taurate is magnesium bound to two molecules of taurine (2-aminoethanesulfonic acid), formula C4H12MgN2O6S2, about 8.9% elemental magnesium by weight. It is a water-soluble salt expected to dissociate in the gut, so the circulating species are magnesium ion and taurine rather than an intact chelate.

Magnesium is a cofactor for more than 300 enzymes. In blood vessels it competes with calcium at L-type calcium channels (voltage-gated pores into muscle cells) and lowers cytoplasmic free calcium, relaxing vascular smooth muscle. In neurons it voltage-blocks the NMDA receptor (N-methyl-D-aspartate, a glutamate-gated calcium channel). Intestinal uptake is paracellular (between-cell) plus TRPM6/TRPM7 channels (transient receptor potential proteins that move magnesium into gut cells); fractional absorption falls as dose rises.

Taurine helps cells manage water and salt, conjugates bile acids, and likewise tends to reduce intracellular calcium; isolated taurine trials report small blood-pressure reductions. The 1996 McCarty hypothesis—written while the author was affiliated with Nutrition 21, which patented the salt—was that the two agents act in parallel on that calcium set-point.

Most body magnesium is stored in bone and inside cells; only about 1% circulates in serum. Taurine concentrates in heart, muscle, brain, and retina. Serum magnesium is tightly buffered, so there is no simple drug-like half-life; excess absorbed magnesium is excreted by the kidney over hours. Taurine’s plasma half-life is about one hour. The salt is not a cytochrome P450 substrate (CYP, a liver enzyme family that oxidizes many drugs) and has no receptor-level selectivity beyond a mineral plus taurine.

Historical Context & Evolution

Magnesium taurate entered the literature as a designed nutrient. In 1996 Mark F. McCarty, at Nutrition 21, argued that magnesium and taurine share antihypertensive, anti-atherosclerotic, anti-arrhythmic, and platelet-stabilizing actions via lower intracellular calcium, and that the combined salt could be given orally or, hypothetically, in place of magnesium sulfate in acute cardiac care and preeclampsia (high blood pressure in pregnancy that can threaten mother and fetus). Related papers extended the same logic to migraine and perinatal asphyxia (oxygen shortage around birth). Nutrition 21 obtained patent coverage (U.S. 5,776,504). Those papers reported a mechanistic rationale and prior magnesium or taurine findings; they did not report a randomized trial of the salt.

The salt is a readily soluble, dissociable magnesium source, with no unique safety flag at supplemental magnesium intakes up to the then-current 250 mg/day upper level, though taurate exposure at that magnesium dose is substantial. Independent academic groups later tested the salt in animals: Shrivastava and colleagues reported blood-pressure and myocardial-antioxidant changes in cadmium-hypertensive rats; Agarwal, Iezhitsa, and Choudhary reported delayed experimental cataract. Human work remained almost absent until a 2026 single-arm series combined magnesium taurate with potassium citrate.

The current picture is therefore mixed rather than settled: a commercially originated hypothesis, a regulator’s “dissociable salt” reading, a thin animal cardioprotection and lens literature, and still almost no controlled human outcome data on the named salt. Magnesium acetyl taurate later attracted separate brain-uptake studies and is a separate chemical history.

Expected Benefits

High 🟩 🟩 🟩

Blood Pressure Reduction

Oral magnesium, tested mainly as citrate, oxide, and chloride rather than taurate, lowered blood pressure in randomized controlled trials (RCTs, studies that randomly assign people to treatment or placebo). A 2025 meta-analysis of 38 trials found about 3 mm Hg systolic and 2 mm Hg diastolic reductions, larger in treated hypertension and low magnesium (Argeros et al., 2025). Isolated taurine produces a similar-sized systolic drop (Waldron et al., 2018). The only human magnesium-taurate series also used potassium citrate, so the salt-specific share is not isolated (Dereli, 2026).

Magnitude: −2.81 mm Hg systolic and −2.05 mm Hg diastolic versus placebo at a median 365 mg elemental magnesium over 12 weeks in mixed-salt RCTs; −7.68 mm Hg systolic in treated hypertension.

Faster Sleep Onset

A three-trial analysis in older adults found 17 minutes faster sleep onset with oral magnesium, a human sleep-onset endpoint replicated across those trials; evidence quality was low and magnesium taurate was not the salt used (Mah & Pitre, 2021). Evening use is common in practice but remains untested for this form.

Magnitude: Sleep onset 17.36 minutes faster versus placebo in 151 older adults; total sleep time not clearly longer.

Fasting Glucose in Type 2 Diabetes

Nine mixed-salt magnesium RCTs in type 2 diabetes lowered fasting glucose by 0.56 mmol/L over a median 12 weeks; glycated hemoglobin (HbA1c, a three-month average blood-sugar marker) did not change significantly (Song et al., 2006). Taurine has a separate, smaller metabolic literature (Tzang et al., 2024). No magnesium-taurate diabetes trial in people was identified. For someone using this salt to replete magnesium, the glucose signal is class-level, not form-proven.

Magnitude: Fasting glucose −0.56 mmol/L (about 10 mg/dL) after a median 360 mg/day for 12 weeks; HbA1c change not significant (−0.31%, confidence interval (the range of values still consistent with the data) crossing zero).

Medium 🟩 🟩

No additional benefit reaches Medium: remaining human findings are either the mixed-salt endpoints already graded High or the uncontrolled or conflicting series graded Low.

Low 🟩

Migraine Prevention ⚠️ Conflicted

A 10-trial meta-analysis found fewer, milder migraines with oral magnesium; a later review called it only possibly effective, with mixed better-controlled trials (Chiu et al., 2016; von Luckner & Riederer, 2018). No taurate-specific human trial exists (McCarty, 1996). Net reading: class evidence is mixed and not form-proven for taurate.

Magnitude: Oral magnesium reduced migraine frequency (odds ratio 0.20, the odds of the outcome on treatment versus control) and intensity (odds ratio 0.27) versus control in mixed-salt prophylaxis RCTs; the literature reports no taurate-only controlled figure.

Arterial Stiffness

In 110 adults, magnesium taurate plus potassium citrate and lifestyle advice lowered pulse-wave velocity by 0.9 m/s. There was no placebo arm, so potassium and behavior change are confounded with taurate (Dereli, 2026).

Magnitude: Pulse-wave velocity −0.9 m/s and augmentation index (−4.0%, a stiffness-related wave-reflection score) at three months in that single-arm series; the literature reports no taurate-only controlled figure.

Speculative 🟨

Myocardial Protection

In cadmium-hypertensive rats, oral magnesium taurate restored blood pressure and heart-tissue antioxidant enzymes versus amlodipine. The basis is animal histopathology and unvalidated oxidative-stress markers, not human events (Shrivastava et al., 2019).

Delayed Experimental Cataract

Oral and topical magnesium taurate delayed galactose- and hypertension-related lens opacity in rats by restoring lens magnesium/calcium balance. No human cataract trial exists (Agarwal et al., 2013; Choudhary & Bodakhe, 2016).

Rhythm Stabilization

McCarty proposed the salt for arrhythmia prevention via the same intracellular-calcium logic used for blood pressure. No human trial of that endpoint exists; the basis is mechanistic only (McCarty, 1996).

Benefit-Modifying Factors

TRPM6 and claudin-16 variants: Rare loss-of-function in TRPM6 (an intestinal magnesium channel) or claudin-16 (a kidney tight-junction protein that reabsorbs magnesium) causes urinary wasting; ordinary oral doses may not restore levels (Schuchardt & Hahn, 2017).
Baseline magnesium: Hypomagnesemic (low blood magnesium) and treated-hypertensive subgroups show larger blood-pressure drops in mixed-salt meta-analyses; people already at the top of the serum range gain less (Argeros et al., 2025).
Sex: Adult men have a higher recommended dietary allowance (400–420 mg versus 310–320 mg elemental magnesium); no taurate-specific sex-outcome trial exists.
Insulin resistance and type 2 diabetes: Class magnesium trials report larger pressure and glucose shifts in these groups; that is a population difference, not a taurate-specific finding (Dibaba et al., 2017).
Age: Intake and absorption fall after 70, and diuretic or acid-suppressing drug use is more common, so the same oral dose may close a larger gap—or hit a smaller renal reserve.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Gastrointestinal Loosening and Diarrhea

Unabsorbed magnesium draws water into the bowel. In pooled oral-magnesium cramp trials, minor gastrointestinal events occurred in 11–37% of magnesium recipients versus 10–14% on placebo, mostly diarrhea (Garrison et al., 2020). Organic salts such as taurate are marketed as gentler than oxide; a taurate-specific rate in people has not been published (Drugs.com magnesium citrate).

Magnitude: Minor gastrointestinal events in 11% to 37% of oral-magnesium recipients versus 10% to 14% on placebo across pooled trials; taurate-specific incidence not quantified.

Medium 🟥 🟥

Hypermagnesemia (high blood magnesium) in Reduced Kidney Function

Severe high blood magnesium—with low blood pressure, muscle weakness, and slowed breathing—is almost exclusive to people with substantially reduced kidney function who take large oral or cathartic magnesium loads (Van Laecke, 2019). It is a documented clinical finding from observational series and case reports, not from more than one controlled trial of this salt. Normal kidneys usually excrete excess absorbed magnesium (Drugs.com magnesium citrate).

Magnitude: Severe hypermagnesemia is reported almost exclusively when high oral or cathartic magnesium meets substantially reduced kidney function; the literature reports no rate for magnesium taurate in people with normal kidneys.

Low 🟥

Additive Light-Headedness with Blood-Pressure Drugs

Magnesium and taurine each lower blood pressure a few mm Hg. Stacked with antihypertensives, the class magnesium reduction plus taurine’s approximately 3 mm Hg can produce symptomatic light-headedness. No taurate-plus-drug RCT exists (Argeros et al., 2025; Waldron et al., 2018).

Magnitude: Direction is additive blood-pressure lowering; the literature reports no outcome figure for magnesium taurate combined with named antihypertensives.

Speculative 🟨

Intact-Chelate or Taurine-Specific Harm at Usual Doses

Safety is inferred from magnesium and taurine’s 3 g/day observed-safe intake in a Council for Responsible Nutrition trade-group paper (Shao & Hathcock, 2008). No unique taurate human toxicology is documented.

Risk-Modifying Factors

Kidney function: Estimated glomerular filtration rate (eGFR, a blood-test estimate of kidney filtering) below 30 mL/min/1.73 m² is the dominant amplifier of hypermagnesemia risk (Van Laecke, 2019).
TRPM6 and claudin-16 variants: Rare intestinal or renal wasting leaves more unabsorbed magnesium in the bowel (more diarrhea) and a smaller absorbed load (less hypermagnesemia) than intact channels.
Baseline magnesium: High-normal serum magnesium plus an extra oral load raises the chance of neuromuscular depression; low baseline is the group that also has more to gain.
Sex: Pregnancy uses parenteral magnesium sulfate for preeclampsia; oral taurate is not that protocol and lacks obstetric safety trials (McCarty, 1996).
Conduction and neuromuscular disease: High-degree atrioventricular block (a severe heartbeat-conduction delay) without a pacemaker, and myasthenia (a disease of fluctuating muscle weakness), change magnesium’s neuromuscular risk.
Age: Older adults have less renal reserve and more loop-diuretic, thiazide, and acid-suppressing drug exposure, so the same milligram dose is not age-neutral.

Key Interactions & Contraindications

Tetracyclines and quinolones (doxycycline, ciprofloxacin): Caution. Magnesium chelates these antibiotics and can cut absorption; separate by at least 2 hours before or 4–6 hours after the antibiotic.
Bisphosphonates (bone-density drugs; alendronate, risedronate): Caution. Magnesium reduces oral uptake; separate by at least 2 hours and follow the empty-stomach rule.
Levothyroxine: Caution. Divalent minerals reduce thyroxine absorption; separate by 4 hours and monitor thyroid-stimulating hormone after a dose change.
Gabapentin: Caution. Magnesium can reduce gabapentin exposure; separate doses and watch seizure or pain control.
Loop and thiazide diuretics (furosemide, hydrochlorothiazide): Monitor. These increase urinary magnesium loss, which can raise the dose needed to replete, not a direct toxic interaction.
Potassium-sparing diuretics (spironolactone, triamterene): Caution. Combined magnesium and potassium retention can raise both cations when eGFR is reduced.
Acid-suppressing drugs (omeprazole, pantoprazole): Monitor. Long-term proton-pump inhibitors (PPIs, drugs that strongly reduce stomach acid) are linked to magnesium wasting; stopping the PPI is a separate decision from taking taurate.
Antihypertensives and other blood-pressure supplements (amlodipine, lisinopril, potassium citrate, extra taurine): Monitor. Additive lowering can cause light-headedness; home blood-pressure logs catch it.
Calcium and high-dose zinc: Monitor. Large co-doses compete for intestinal uptake; split from the magnesium dose.

Populations who should avoid Magnesium Taurate:

Severe chronic kidney disease (eGFR <30 mL/min/1.73 m²) or dialysis without specialist-directed magnesium use
High-degree atrioventricular block without a pacemaker
Myasthenia gravis with clinically unstable neuromuscular function
Known magnesium hypersensitivity

Risk Mitigation Strategies

Elemental-dose cap: Protocols typically hold supplemental elemental magnesium at or below 350 mg/day (U.S. upper level) unless treating documented deficiency, to limit diarrhea and hypermagnesemia.
Split doses: The daily amount is commonly divided into two or three doses with food so unabsorbed magnesium in any one sitting is smaller, reducing osmotic diarrhea.
Kidney gate: eGFR is typically checked before starting; doses are not self-escalated when eGFR is below 60 mL/min/1.73 m², to avoid magnesium accumulation.
Drug-timing window: Taurate is typically separated from tetracyclines, quinolones, bisphosphonates, and levothyroxine by several hours to prevent chelation failures of those drugs.
Home blood-pressure log: Morning and evening readings for the first 2–4 weeks when stacked with antihypertensives catch additive light-headedness.
Label arithmetic: The elemental magnesium line, not milligrams of “magnesium taurate” compound (~8.9% magnesium by weight), is the figure used to avoid under- or over-dosing.

Therapeutic Protocol

Practitioner pattern: Longevity-oriented clinicians who use this salt treat it as an organic magnesium source aimed at blood pressure and sleep onset, typically 200–350 mg elemental magnesium/day, not as a unique drug (Kresser insomnia article; Attia AMA #54).
Competing approaches: Conventional practice uses mixed magnesium salts or food first; integrative practice often prefers glycinate for sleep or citrate for constipation. Taurate is the cardiovascular-framed alternative, not a default.
Time of day: Evening dosing is common when sleep onset is the aim; morning-plus-evening splits suit blood-pressure repletion and reduce the intestinal magnesium load.
Half-life: Serum magnesium is homeostatically buffered rather than following a simple drug half-life; excess is excreted by the kidney over hours. Taurine’s plasma half-life is about one hour.
Single versus split: Split doses raise fractional absorption versus one large load (Schuchardt & Hahn, 2017).
Genetics: TRPM6 or claudin-16 loss-of-function wasting is rare; ordinary oral taurate is then insufficient and needs specialist magnesium handling.
Sex: The higher male dietary target (400–420 mg/day from food plus supplement) is the usual planning ceiling, not a taurate-specific efficacy split.
Age: After 70, protocols typically begin at the low end (about 100–200 mg elemental) because renal reserve is smaller.
Baseline magnesium: When serum magnesium is already high-normal, adding more is not the logic that the class blood-pressure data support.
Kidney and gut disease: Reduced eGFR or active inflammatory bowel disease changes both dose and the decision to use any oral magnesium.

Discontinuation & Cycling

Duration: Magnesium repletion is ongoing while intake remains low; it is not a short course with a defined stop date, nor a lifelong drug commitment.
Withdrawal: No magnesium-taurate withdrawal syndrome is described; serum levels fall back toward the dietary set-point over days as the extra load stops.
Taper: Tapering is not required for physiologic doses. If the salt was being used at laxative-range amounts, stepping down reduces rebound constipation.
Cycling: No tachyphylaxis (loss of effect from continuous use) is established for magnesium; cycling is not used to preserve efficacy.
After stopping antihypertensives or diuretics: Blood pressure and serum magnesium are typically rechecked, because the magnesium gap and the additive pressure effect both change.

Sourcing and Quality

Identity: This salt is labeled magnesium taurate or magnesium ditaurate, not only “magnesium” and not magnesium acetyl taurate / acetyl taurinate, a different compound.
Elemental content: Products that state milligrams of elemental magnesium are the usable figure; ~8.9% by weight means 200 mg elemental requires about 2.2 g of pure ditaurate compound.
Oxide buffers: Some “taurate” products are buffered with magnesium oxide. That raises elemental milligrams but reintroduces the poorly absorbed, more laxative salt; the Supplement Facts panel shows it.
Third-party testing: USP, NSF, or ConsumerLab marks reduce the chance of under-filled elemental magnesium or undeclared oxide.
Historical brands: Cardiovascular Research magnesium taurate sits in the McCarty/Nutrition 21 lineage; NOW and similar independent brands sell the salt as a commodity chelate. None of these replaces a certificate of analysis.

Practical Considerations

Time to effect: Mixed-salt blood-pressure trials used a median 12 weeks; sleep-onset changes, when present, appear within days to a few weeks. Taurate-specific timing is not established.
Label pitfall: Treating “500 mg magnesium taurate” as 500 mg elemental magnesium under-doses by about ten-fold; the reverse error overshoots the gut and the kidney.
Form mix-up: Magnesium acetyl taurate (ATA-Mg) is marketed for brain uptake and is not interchangeable with magnesium taurate.
Regulatory status: In the United States this is a dietary supplement, not an FDA-approved drug; structure/function claims are manufacturer language, not a reviewed indication.
Cost: Specialty taurate capsules cost more per milligram of elemental magnesium than citrate or glycinate but are not in a scarce-drug price class.

Interaction with Foundational Habits

Sleep: Direct, possibly potentiating. Class magnesium can shorten sleep onset; taurine is GABAergic (it supports the brain’s main calming transmitter). Evening dosing is the practical alignment; diarrhea from a large night dose can fragment sleep instead.
Nutrition: Direct. Phytate and oxalate modestly cut magnesium absorption; protein and splitting the dose help. Large calcium or zinc boluses compete; a high-protein, green-vegetable pattern supplies magnesium that the supplement is meant to top up, not replace.
Exercise: Indirect, potentiating need. Sweat and stress-hormone output increase magnesium losses; there is no evidence that taurate blunts hypertrophy. Heavy training is a reason to track intake, not to time the capsule around the workout.
Stress management: Indirect. Magnesium participates in the hypothalamic–pituitary–adrenal stress axis and NMDA-receptor tone; taurine supports inhibitory signaling. The salt does not replace sleep, light, or psychological methods, and high cortisol itself increases magnesium wasting.

Monitoring Protocol & Defining Success

Before starting, a baseline panel establishes kidney clearance, magnesium status, and the blood-pressure or glucose target. The same panel is typically repeated at 4 weeks, then every 3–6 months while the dose is stable, or sooner if a diuretic, acid-suppressing drug, or antihypertensive is added. Success is a documented move toward mid-to-high-normal magnesium without diarrhea or a falling eGFR, plus a home blood-pressure trend in the small class-level range. Red-cell magnesium is used by some clinics as a tissue proxy; it is not a validated surrogate and does not outrank serum magnesium plus eGFR. If nothing measurable changes by 12 weeks at 200–350 mg elemental magnesium/day, the salt has not shown an effect in that person.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Serum magnesium	2.0–2.3 mg/dL (0.82–0.95 mmol/L)	Confirms the oral load is landing and not overshooting	Conventional labs often flag only below ~1.7 mg/dL; draw without a recent large oral dose
RBC magnesium	Track change from that person’s baseline; no established functional target	Some clinics use it as a tissue proxy	Red-cell magnesium; fasting not required; not a substitute for serum magnesium plus eGFR
eGFR (creatinine or cystatin C)	≥60 mL/min/1.73 m² to continue unsupervised oral magnesium	Gates hypermagnesemia risk	Conventional “normal” is ≥90; below 30 is an avoid threshold
Home blood pressure	Individual target, often <120/80 mm Hg if tolerated	The main clinical surrogate this salt is chosen for	Morning and evening, same arm, 1 week of readings before judging
Fasting glucose or HbA1c	Fasting glucose 70–90 mg/dL if pursuing metabolic optimization; HbA1c as that person’s trend	Class magnesium signal is glucose, not HbA1c	Conventional fasting glucose is typically 70–99 mg/dL; HbA1c needs no fasting
Serum potassium	4.0–4.5 mmol/L when stacked with potassium citrate or sparing diuretics	Dual-cation retention in low eGFR	Conventional labs often use 3.5–5.0 mmol/L; pair with magnesium if using a potassium-containing combination product

Qualitative markers:

Stool form (formed sausage-shaped stool, Bristol 4, as the practical ceiling before dropping the dose)
Evening relaxation and sleep-onset latency without next-day grogginess
Absence of flushing, heavy legs, or new light-headedness on standing
Training recovery and muscle cramp frequency, interpreted cautiously because oral magnesium has not shown clear cramp prophylaxis in older adults (Garrison et al., 2020)

Emerging Research

No taurate registration: No ClinicalTrials.gov study of magnesium taurate, magnesium ditaurate, or magnesium taurinate was indexed as of 23 August 2026, so form-specific human evidence is not in the pipeline under those names.
Organic-salt blood pressure: Effect of Magnesium Supplementation on Elevated Systolic Blood Pressure (NCT05690464) is an active, not-recruiting trial of magnesium glycinate in 120 people. A clear null result would weaken the class organic-salt blood-pressure case that taurate currently borrows; a positive result would still not prove taurate.
Magnesium and sleep: Improving Sleep Health Through Magnesium Supplementation (NCT07359612) tests 250 mg magnesium in 65 people. A null sleep finding would undercut evening-taurate practice that rests on class magnesium, not on this salt.
Taurine and aging: Singh and colleagues reported taurine decline as an aging driver in animals (Singh et al., 2023). Human confirmation would strengthen the taurine half of the pairing; failure to translate would leave taurate as “just another magnesium salt.”
Confounded human series: Dereli’s 2026 single-arm magnesium taurate–potassium citrate study (Dereli, 2026) is a template for a placebo-controlled taurate-only RCT. A negative RCT would collapse the form-specific human case.
Related-compound confusion: Ongoing magnesium acetyl taurate (ATA-Mg) work is a different molecule with a different brain-uptake claim and is not magnesium-taurate evidence.

Conclusion

Magnesium taurate is an oral magnesium salt that also supplies taurine. For health- and longevity-oriented adults who already accept inconvenient protocols, its practical case is as a well-tolerated way to close a magnesium gap while adding a nutrient that has its own blood-pressure signal. Blood-pressure and fasting-glucose effects that can be claimed with any confidence are those of absorbable magnesium as a class, not of this salt in isolation. Direct human evidence on magnesium taurate itself is a single study with no comparison group that also used potassium citrate, plus animal work on heart tissue and the lens.

The main documented harms are the same as for other oral magnesium salts: loose stool, and a real risk of magnesium buildup when the kidneys cannot clear the mineral. Early papers that popularized the salt came from a nutrition-company scientist with a commercial stake in the compound; a later taurine safety assessment used here was produced for a supplement-industry trade group. Later animal work is independent of those sources. Magnesium acetyl taurate is a different chemical and does not substitute for this evidence.

Taken together, magnesium taurate is a reasonable, well-absorbed magnesium salt when blood pressure and a combined taurine dose are the reason for choosing the salt. It is not a separately proven longevity agent, and the size of its human outcome literature remains small.

Top - Benefits - Risks - Protocol

Magnesium Taurate for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

High 🟩 🟩 🟩

Blood Pressure Reduction

Faster Sleep Onset

Fasting Glucose in Type 2 Diabetes

Medium 🟩 🟩

Low 🟩

Migraine Prevention ⚠️ Conflicted

Arterial Stiffness

Speculative 🟨

Myocardial Protection

Delayed Experimental Cataract

Rhythm Stabilization

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Gastrointestinal Loosening and Diarrhea

Medium 🟥 🟥

Hypermagnesemia (high blood magnesium) in Reduced Kidney Function

Low 🟥

Additive Light-Headedness with Blood-Pressure Drugs

Speculative 🟨

Intact-Chelate or Taurine-Specific Harm at Usual Doses

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion